OOIR: Observatory of International Research

Papers

(The H4-Index of Journal of Psychopharmacology is 29. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)

Article	Citations
Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up	140
Ketamine: A tale of two enantiomers	97
Adverse effects of psychedelics: From anecdotes and misinformation to systematic science	83
Pivotal mental states	66
Survey of entity encounter experiences occasioned by inhaled N,N-dimethyltryptamine: Phenomenology, interpretation, and enduring effects	61
Development of the Psychological Insight Questionnaire among a sample of people who have consumed psilocybin or LSD	61
Changes in inflammatory biomarkers are related to the antidepressant effects of Ayahuasca	56
Efficacy of psychedelic treatments on depressive symptoms: A meta-analysis	51
First study of safety and tolerability of 3,4-methylenedioxymethamphetamine-assisted psychotherapy in patients with alcohol use disorder	49
Transcriptional regulation in the rat prefrontal cortex and hippocampus after a single administration of psilocybin	48
Optimal dosing for psilocybin pharmacotherapy: Considering weight-adjusted and fixed dosing approaches	48
Subacute effects of the psychedelic ayahuasca on the salience and default mode networks	47
Efficacy and Tolerability of Combination Treatments for Major Depression: Antidepressants plus Second-Generation Antipsychotics vs. Esketamine vs. Lithium	47
A low dose of lysergic acid diethylamide decreases pain perception in healthy volunteers	46
Validation of the Psychological Insight Scale: A new scale to assess psychological insight following a psychedelic experience	43
Associations between lifetime classic psychedelic use and markers of physical health	39
Brain serotonin 2A receptor binding predicts subjective temporal and mystical effects of psilocybin in healthy humans	38
Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review	38
Ketamine’s effect on inflammation and kynurenine pathway in depression: A systematic review	38
Psychedelics and health behaviour change	37
Acute subjective effects in LSD- and MDMA-assisted psychotherapy	37
Does cannabis complement or substitute alcohol consumption? A systematic review of human and animal studies	35
Modulation of microglial activation by antidepressants	34
Mystical-type experiences occasioned by ketamine mediate its impact on at-risk drinking: Results from a randomized, controlled trial	34
Dose–response relationships of psilocybin-induced subjective experiences in humans	34

Characterisation of the pharmacodynamic effects of the P2X7 receptor antagonist JNJ-54175446 using an oral dexamphetamine challenge model in healthy males in a randomised, double-blind, placebo-contro	32
A qualitative and quantitative account of patient’s experiences of ketamine and its antidepressant properties	31
The effects of psilocybin on cognitive and emotional functions in healthy participants: Results from a phase 1, randomised, placebo-controlled trial involving simultaneous psilocybin administration an	31
Hallucinogenic/psychedelic 5HT2A receptor agonists as rapid antidepressant therapeutics: Evidence and mechanisms of action	30
The epidemiology of mescaline use: Pattern of use, motivations for consumption, and perceived consequences, benefits, and acute and enduring subjective effects	29